Brief ReportInterferon treatment for corneolimbal squamous dysplasia
References (5)
- et al.
Clinical and pathological description of 17 cases of corneal intraepithelial neoplasia
Am J Ophthalmol
(1984) - et al.
The interferons: mechanisms of action and clinical applications
JAMA
(1991)
Cited by (32)
Clinic-pathological agreement in the diagnosis of conjunctival tumours: Analysis of 195 cases
2023, Archivos de la Sociedad Espanola de OftalmologiaComparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia
2019, American Journal of OphthalmologyCitation Excerpt :Since then, several studies encompassing 332 individuals have evaluated its use as a primary agent in OSSN, again with a high frequency of resolution (average 95%, range 75%-100%). Similar to 5FU, recurrences were uncommon (range 4%-20%) and most occurred in the first year.3,20,28,29,31–37 Our 81% frequency of resolution fits well within this range.
Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia Presented Cornea Society/Fall Educational Symposium, November 2015, Las Vegas, Nevada.
2016, OphthalmologyCitation Excerpt :In our study, representing the largest group of patients treated with 5-FU as primary therapy to date, we found that 82% of patients experienced complete resolution of OSSN. Our response frequency of 82% for 5-FU is similar to what has been reported in larger series of IFN- and MMC-treated patients.11,20–26,28–35 One issue in comparing treatment response between 5-FU studies is that varying regimens have been used to treat OSSN.
Local chemotherapeutic agents for the treatment of ocular malignancies
2014, Survey of OphthalmologyCitation Excerpt :The use of IFN-α2b in the treatment of OSSN was first attempted by Maskin et al in their patient who had regression of a recurrent limbal epithelial lesion previously treated with surgical excision and cryotherapy.97 Later, Hu et al demonstrated that both subconjunctival and topical therapy resulted in clinical resolution of a dysplastic squamous lesion after 2 months of treatment.72 IFN-α2b may be effective when prior surgical excision, cryotherapy, and MMC have failed.70,111
Topical Interferon or Surgical Excision for the Management of Primary Ocular Surface Squamous Neoplasia
2008, OphthalmologyCitation Excerpt :All deep, lateral, and posterior surgical margins were tumor free by histopathology. Successful use of topical interferon alfa-2b as sole therapy for primary OSSN was previously reported in 15 patients in 5 previously published series (Table 3),50–52,55,58 with only 1 patient observed for more than 16 months.51 Our 13 patients successfully treated with topical interferon alfa-2b for primary OSSN bring the total number of patients in the published literature with primary OSSN successfully treated with topical interferon alfa-2b to 28, with a median disease-free follow-up of 12.5 months (data not shown).
Treatment of conjunctival squamous neoplasias with interferon alpha 2b
2008, Journal Francais d'Ophtalmologie
- *
Inquiries to Fung-Rong Hu, MD, Department of Ophthalmology, National Taiwan University Hospital, 7 Chung-Shan S Road, Taipei, Taiwan; fax: 886-2-3412875.